{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.16","upperLimit":"0.27","value":"0.18"},{"groupId":"OG001","lowerLimit":"0.41","upperLimit":"1.03","value":"0.60"},{"groupId":"OG002","lowerLimit":"0.52","upperLimit":"1.09","value":"0.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"107"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from registration to the time of progression or death due to any cause. Progression-free survival was estimated using the method of Kaplan-Meier.\n\nProgression is defined as the following:\n\nCLL (subset of patients in the Relapsed Indolent Non-Hodgkin Lymphoma group): \\>=50% increase in nodes from nadir or \\>=50% increase in liver/spleen size from nadir.\n\nWaldenstrom (subset of patients in the Uncommon Lymphomas group): \\>50% lymph node increase in SPD of \\> 1 node or new nodes, or \\>50% liver/spleen size increase, or \\> 25% IgM (by SPEP) increase, or lymphocyte morphology transformation to a more aggressive histology.\n\nAll Others: New lesions or \\>=50% lymph nodes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Study 1.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG000","title":"Relapsed Aggressive Non-Hodgkin Lymphoma"},{"description":"Study 2.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG001","title":"Relapsed Indolent Non-Hodgkin Lymphoma"},{"description":"Study 3. Includes Hodgkin's lymphomas.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"OG002","title":"Uncommon Lymphomas"}],"paramType":"MEDIAN","populationDescription":"276 out of 277 were analyzed for response. One patient was excluded because of patient refusal before starting treatment.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"years"}